U.S. markets close in 3 hours 59 minutes

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.4850-0.1950 (-7.28%)
As of 12:01PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close2.6800
Bid2.5100 x 3000
Ask2.5200 x 800
Day's Range2.4700 - 2.7250
52 Week Range2.4100 - 6.5000
Avg. Volume10,034,970
Market Cap363.218M
Beta (5Y Monthly)2.66
PE Ratio (TTM)N/A
EPS (TTM)-0.9170
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ABUS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arbutus Biopharma Corporation
    Analyst Report: Johnson & JohnsonJohnson & Johnson is a diversified healthcare company that develops, manufactures and markets products in three primary lines of business: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Products.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more

    First Quadrant L P Buys Innoviva Inc, NOW Inc, General Electric Co, Sells , Brookfield Asset ...

    Investment company First Quadrant L P (Current Portfolio) buys Innoviva Inc, NOW Inc, General Electric Co, CF Industries Holdings Inc, JPMorgan Chase, sells , Brookfield Asset Management Inc, , Roku Inc, Cardiovascular Systems Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Quadrant L P.

  • GlobeNewswire

    Arbutus Announces 2022 Corporate Objectives and Provides Financial Update

    Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV Complete IND-enabling studies for next generation oral RNA destabilizer, AB-161, for the treatment of HBVAdvance an nsp5 main protease (Mpro) inhibitor candidate into IND-enabling studies for treatment of SARS-CoV-2 Financial position significantly strengthened; cash runway into Q2

  • Zacks

    Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?

    Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.